GlassScriptPhysician profile
Omid Saeed Tehrani
NPI 1659508281
$6,745.82
in general payments reported to CMS, 2019-2025
52 companies · $1,853 in 2025
The $1,853 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.34 · 2021: $1,368 · 2022: $595 · 2023: $965 · 2024: $1,927 · 2025: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,721 · Education: $23.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,720.78 |
| Education | $23.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $622.72 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $490.79 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $466.81 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $462.34 | 2021-2025 | Enhertu, Tagrisso, Calquence |
| E.R. Squibb & Sons, L.L.C. | $343.62 | 2021-2025 | Opdualag, Opdivo |
| Celgene Corporation | $321.60 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $225.09 | 2021-2025 | |
| Genentech USA, INC. | $214.45 | 2021-2025 | Tecentriq, Venclexta, Polivy |
| Amgen INC. | $191.67 | 2021-2023 | Lumakras |
| Glaxosmithkline, LLC. | $183.80 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $183.28 | 2019-2025 | |
| Lilly USA, LLC | $177.47 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $177.42 | 2022-2025 | |
| Daiichi Sankyo INC. | $165.47 | 2021-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $163.55 | 2022-2025 | Libtayo, Lynozyfic |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $161.02 | 2023-2024 | Krazati |
| Incyte Corporation | $158.93 | 2021-2025 | Monjuvi, Jakafi, Niktimvo |
| Astellas Pharma US INC | $136.25 | 2021-2025 | Xtandi, Vyloy, Xospata |
| Exelixis INC. | $131.67 | 2021-2025 | Cabometyx |
| Genzyme Corporation | $122.23 | 2021-2025 | |
| Gilead Sciences, INC. | $121.23 | 2021-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $108.34 | 2024-2025 | Besremi |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $93.70 | 2024-2025 | Onivyde |
| Tempus Ai, INC | $80.51 | 2024-2025 | Xt Cdx |
| Stemline Therapeutics INC. | $78.53 | 2023-2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.21 | 2023-2025 | Gilotrif |
| Adc Therapeutics America, INC. | $68.11 | 2024-2025 | |
| Abbvie INC. | $66.34 | 2023-2024 | Venclexta |
| Taiho Oncology, INC. | $64.27 | 2021-2024 | |
| Servier Pharmaceuticals LLC | $60.40 | 2025 | |
| Karyopharm Therapeutics INC. | $57.38 | 2021-2025 | Xpovio |
| Emd Serono, INC. | $54.66 | 2022-2024 | Bavencio |
| Seagen INC. | $54.63 | 2021 | |
| Deciphera Pharmaceuticals INC. | $53.76 | 2022-2024 | Qinlock |
| Beone Medicines USA, INC. | $47.46 | 2025 | Brukinsa, Tevimbra |
| Array Biopharma INC | $47.36 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Puma Biotechnology, INC. | $45.92 | 2021-2024 | |
| Beigene USA, INC. | $44.68 | 2023-2025 | Brukinsa |
| Medtronic, INC. | $40.75 | 2024 | Synchromedii |
| Springworks Therapeutics, INC. | $38.97 | 2024-2025 | Ogsiveo |
| Morphosys, US INC. | $37.59 | 2021-2023 | Monjuvi |
| Immunogen, INC. | $36.51 | 2023 | Elahere |
| Takeda Pharmaceuticals U.S.A., INC. | $26.01 | 2024 | Ninlaro |
| Geron Corporation | $25.84 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $23.77 | 2024 | Sylvant |
| Clovis Oncology, INC. | $20.09 | 2022 | |
| Tactile Systems Technology INC | $17.73 | 2021 | |
| Cti Biopharma Corp. | $16.55 | 2023 | Vonjo |
| Pharmacosmos Therapeutics INC. | $15.69 | 2024 | Monoferric |
| Aveo Pharmaceuticals, INC. | $15.67 | 2021 | |
| Dova Pharmaceuticals | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Saeed Tehrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.